Loading rounds…
Loading rounds…
Explore funding rounds, the companies behind them and the investors taking part.
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| TB Transcripta BioCompany profile AI-powered drug discovery company developing treatments for neurological and neuromuscular diseases AI-powered drug discovery company developing treatments for neurological and neuromuscular diseases | $24M | Series A | Biotech | United States | Investors | |
| CT |
Ranked by rounds participated in · All time
AusperBio, Abcuro, Infinimmune
Epicrispr Biotechnologies, Draig Therapeutics, Triveni Bio
LifeMine Therapeutics, Ollin Biosciences, SonoThera
Leal Therapeutics, Khartis Therapeutics, Vedana Therapeutics
Leal Therapeutics, Amplifica Holdings Group, InduPro
Explore published rounds while the next edition is being prepared.
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
| $130M |
| Series B |
| Biotech |
| United States |
| Investors |
| NB N-Zyme BiomedicalCompany profile Developing first-in-class therapies targeting pepsin for reflux disease Developing first-in-class therapies targeting pepsin for reflux disease | $4.6M | Series A | Biotech | United States | Investors Undisclosed |
| RN Rege Nephro CoCompany profile Developing innovative therapies and medical technologies for patients with kidney diseases who currently have limited treatment options Developing innovative therapies and medical technologies for patients with kidney diseases who currently have limited treatment options | $10.6M | Series CSeries C+ | Biotech | Japan | Investors |
| ET Estrigenix TherapeuticsCompany profile Developing selective estrogen receptor-beta therapeutics for women's health and neurodegenerative diseases Developing selective estrogen receptor-beta therapeutics for women's health and neurodegenerative diseases | $2M | Seed | Biotech | United States | Investors |
| BP Brenus PharmaCompany profile Develops an off-the-shelf in vivo immunotherapy platform for solid tumors Develops an off-the-shelf in vivo immunotherapy platform for solid tumors | €11M | Series A | Biotech | France | Investors |
| SB Sightera BiosciencesCompany profile Belgian techbio company using generative AI to develop novel small-molecule therapies Belgian techbio company using generative AI to develop novel small-molecule therapies | €3M | Pre-SeedPre-seed | Biotech | Belgium | Investors |
| TB Trellis BioscienceCompany profile Developing native human monoclonal antibodies to treat intractable infectious diseases Developing native human monoclonal antibodies to treat intractable infectious diseases | $9M | Series CSeries C+ | Biotech | United States | Investors |
| A Develops lead-212 targeted alpha therapies to treat cancer | $315M | Series DSeries C+ | Biotech | Australia | Investors AbingworthAlly Bridge Group +17Alpha WaveBain Capital Life SciencesBrandon CapitalCatalio Capital ManagementEli Lilly and CompanyEventide Asset ManagementFidelity Management & Research CompanyMorningsidePiper HeartlandProto AxiomSanofi VenturesSV Health InvestorsSymBiosisTenmileTime BioVenturesT. Rowe Price AssociatesVelosity Capital |
| N NousCompany profile Develops functional ingredients for the food, beverage and nutraceutical industries Develops functional ingredients for the food, beverage and nutraceutical industries | €2.3M | Seed | Biotech, Foodtech | Italy | Investors |